Boston Scientific acquires radiofrequency ablation company as it expands portfolio

Global medical technology company Boston Scientific acquired Cosman Medical, a Burlington, Massachusetts, radiofrequency ablation system manufacturer.

Boston Scientific, headquartered in Marlborough, Massachusetts, announced the acquisition today in a statement. The move will help them better provide physicians and patients options to address chronic pain using non-opioid therapeutic treatments.

They offer a range of spinal cord stimulator systems designed to alleviate pain. They also use deep brain stimulation systems to treat Parkinson’s disease, dystonia and essential tremor.

"This acquisition is a natural extension of our current product portfolio,” said Maulik Nanavaty, senior vice president and president of neuromodulation at Boston Scientific, in a statement. “The addition of the Cosman Medical product line, which is built on industry-leading technology and known for its high-quality, expands our capability to provide innovative solutions for the treatment of chronic pain."

Katherine Davis,

Senior Writer

As a Senior Writer for TriMed Media Group, Katherine primarily focuses on producing news stories, Q&As and features for Cardiovascular Business. She reports on several facets of the cardiology industry, including emerging technology, new clinical trials and findings, and quality initiatives among providers. She is based out of TriMed's Chicago office and holds a bachelor's degree in journalism from Columbia College Chicago. Her work has appeared in Modern Healthcare, Crain's Chicago Business and The Detroit News. She joined TriMed in 2016.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.